

Cyclin genes as potential novel prognostic biomarkers and therapeutic targets in breast cancer

NIAN-QIU LIU^{1,2*}, WEI-HAN CAO^{3*}, XING WANG^{1,2}, JUNYAO CHEN^{1,2} and JIANYUN NIE^{1*}

¹Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center; ²Kunming Medical University; ³Department of Ultrasound, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China

Received March 9, 2022; Accepted August 15, 2022

DOI: 10.3892/ol.2022.13494

Abstract. Cell cycle progression and cell proliferation are tightly controlled processes physiologically; however, in cancerous cells, uncontrolled cell proliferation may be attributed to abnormal expression of the cyclin genes. Therefore, analysis of the expression of the cyclin genes may result in the discovery of biomarkers that can be used to predict a prognosis and help to evaluate the therapeutic efficacy more accurately in several types of cancer, including breast cancer. In this study, 15 subtypes of the cyclin genes in breast cancer from public databases were selected using bioinformatics analysis, the correlation between their transcriptional expression levels and survival rates were analyzed, and the results were further confirmed using reverse transcription-quantitative PCR *in vitro* in various breast cancer cell lines. The expression of the majority of the cyclin genes in SK-BR-3, a HER2 overexpressing breast cancer cell line, was lower than that in MCF-10A cells. CCNC mRNA expression was higher and CCNH mRNA expression was lower in tumor and tumor-adjacent tissues compared with that in normal tissues; however, CCNC expression was lower and CCNH expression was higher in breast cancer cell lines compared with that in MCF-10A cells. The expression of the 13 other cyclin genes in breast cancer cell lines was generally consistent with the data from the bioinformatics analyses of breast cancer tissue samples, tumor-adjacent tissues, and normal tissues. Low expression of *CCNA2*, *CCNB1/2*, *CCNC*, *CCND1*, *CCNE1/2* and *CCNF*, and high expression of *CCNA1*, *CCNB3*, *CCND2/3*, *CCNG1/2* and *CCNH* genes was correlated with a higher survival rate for breast cancer patients ($P < 0.05$). In conclusion, *CCNA2*,

CCNB1/2, *CCND1/2* and *CCNE1/2* may serve as relatively mature and accurate biomarkers, and *CCNG1/2* may be used to evaluate the prognosis and therapeutic efficacy of hormone receptor-positive breast cancer. Furthermore, *CCNA1*, *CCNB3*, *CCNC*, *CCND3*, *CCNF* and *CCNH* may serve as promising targets for the management of breast cancer.

Introduction

Physiologically, cell cycle progression and cell proliferation are under precise and coordinated control, whereas uncontrolled cell proliferation caused by abnormal cell cycle progression is a key feature of cancer development/progression. Understanding the progression and regulation of the cell cycle is of significant importance for improving cancer treatments (1). The cell cycle consists of a G1 phase, S phase (DNA synthesis), G2 phase, and M phase (mitosis), and each step is jointly regulated by cyclin proteins and related cyclin-dependent kinases (CDKs) (2). To date, eight types of cyclin proteins, cyclin A to H, have been identified in mammalian cells (2,3), and can be further divided into multiple sub-types depending on their functions. It has been widely shown that cyclin genes play regulatory roles in a variety of cancers (4), including urinary malignant tumors (5,6), digestive tract malignant tumors (7,8), reproductive malignant tumors (9,10), and respiratory malignant tumors (11), amongst others.

Breast cancer is caused by the uncontrolled proliferation of breast epithelial tissue cells and is affected by various carcinogenic factors, the environment, genetics, and other factors (12). Based on the presence or absence of marker proteins including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER-2), and Ki-67, breast cancer can be classified into four subtypes, namely luminal A, luminal B, HER-2 enriched, and triple-negative (13). According to the 2020 Global Cancer Statistics (14), breast cancer not only ranks highest amongst the most common malignant tumors in women worldwide, but also surpasses lung cancer as the most commonly diagnosed cancer. Breast cancer is an extremely heterogeneous malignant tumor with inter-tumor and intra-tumor variability (15). Therefore, novel molecular mechanisms and biomarkers for improving the detection of early-stage breast cancer and management of breast cancer are needed, with a long-term goal of improving individualized therapy.

Correspondence to: Professor Jianyun Nie, Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, 519 Kunzhou Road, Xishan, Kunming, Yunnan 650000, P.R. China
E-mail: njyvip@sina.com

*Contributed equally

Key words: biomarker, gene target, cyclin, bioinformatics, breast cancer

Although there are several causes underlying the development of breast cancer, the cyclin family of genes has consistently been shown to play a pivotal role in aberrant cell cycle progression. CyclinA genes are divided into CCNA1 and CCNA2. CCNA1 exerts differential effects in different diseases (10,16), whereas there are fewer studies on the role of CCNA1 in breast cancer (17). CyclinA2 is widely upregulated in a variety of cancers (18) and plays a significant role in regulating the cell cycle (19,20).

CCNB1 is expressed in almost all tissues in humans and is highly expressed in a variety of cancers (21). It binds to CDK1 to form a complex, a key factor regulating the G2-to-M transition and mitotic progression (22). In solid tumors, the expression of CCNB1 is considered a substantial prognostic parameter (4,23). CyclinB2 also binds to CDK1 to form a complex, which inhibits the G2-to-M transition, thereby inducing cell cycle arrest (24). The expression of CCNB2, an oncogene, is upregulated in several types of malignant tumors (7,24-26), and its upregulated expression is associated with a poor prognosis. CyclinB3 possesses homology with cyclinA and cyclinB1/2, and is expressed in animals, insects, and human tissue (27). CCNB3 is more interrelated with BCOR, which encodes the BCL6 co-repressor for co-transcriptional expression, and does not appear to exhibit any obvious specificity in its upregulation regarding cancer type (28-30).

In contrast with other the cyclin genes, the function of CCNC-encoding cyclinC remains largely unknown. It binds to CDK3 and regulates the cell cycle in the G1 and G2 phases, and stimulates the reactivation of the cell cycle from a resting state (31,32). CCNC was shown to be upregulated (33) and increased cell proliferation in 82.6% of breast cancer cases (34).

D-type cyclins can bind to CDK4/6 and phosphorylate various substrates involved in the G1-to-S phase transition (35). In >50% of breast cancer subtypes, cyclinD1 protein expression is upregulated (36-38) and this in turn reduces the efficacy of treatments (39). The specificity of CCND1 expression for the differential diagnosis of benign and malignant mesothelial hyperplasia has been shown to approach 100% (40). CCND2 is one of the essential factors affecting endocrine resistance in breast cancer (41). Hypermethylation of CCND2 significantly increases the risk of death and is deemed an independent factor of a poor prognosis in triple-negative breast cancer (42,43). A meta-analysis showed that the upregulated expression of CCND3 was related to poorer overall survival (OS) in breast cancer and bladder cancer patients (44).

Overexpression of cyclinE1 and cyclinE2 accelerates cell cycle progression by shortening the G1-to-S phase transition period, and promoting cell proliferation and tumorigenesis, resulting in poorer survival rates (45-48). CCNE1 is expressed in all stages of the cell cycle, and accumulates in the S phase, reaching a peak in the G2 phase and gradually declining in the M phase (3). Its expression in different types of cancer varies (49), for example, its expression is low in liver cancer (50), high in gastric cancer (51), and unknown in breast cancer (52).

CCNG1-encoding cyclinG1 was identified as a target of p53-regulated transcription (53). Several studies have shown that CCNG1, which is hypothesized to be an estrogen regulatory

gene (54), is downregulated in breast cancer (55-57). CCNH typically binds to CDK7 and promotes cancer cell migration during carcinogenesis (58). It has been shown that high expression of CCNH is correlated with a poor prognosis in patients with lung cancer (58) and gastrointestinal cancer (8). However, the related role of CCNH in breast cancer has been difficult to determine.

All types of cyclin genes are associated in some manner with the prognosis and/or drug tolerance in breast cancer. Thus far, certain cyclin genes have been verified as biomarkers in the prognostic prediction, evaluation of curative effects, and exploration of drug tolerance mechanisms. Yet, the role/effects of the remainder of the cyclin genes in breast cancer are incompletely understood. Therefore, in this study, bioinformatics methods were used to analyze data from publicly available databases to investigate the expression and mutation of different cyclin genes in breast cancer, attempting to excavate novel biomarkers.

Material and methods

Cell culture. All cell lines used in the present study were obtained from ATCC, including MCF-10A (normal breast tissue cells), MCF-7 (hormone receptor-positive breast cancer cells), MDA-MB-231, MDA-MB-468, and BT-549 (triple negative breast cancer cell lines), and SK-BR-3 (HER2 positive breast cancer cells). All breast cancer cell lines were maintained in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (NEWZERUM, Ltd.), and 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.). MCF-10A cells were cultured in DMEM/F12 supplemented with 5% (vol/vol) horse serum, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, and 500 ng/ml hydrocortisone (MCF-10A specific medium; CM-0525-125; Procell Life Science & Technology Co., Ltd.). All cell lines were maintained at 37°C in a humidified incubator supplied with 5% CO₂.

Reverse transcription-quantitative (RT-q)PCR. Cells were plated in 6-well plates and cells in the logarithmic growth phase were used for RNA extraction. Total RNA was extracted using an ESScience RNA-Quick Purification Kit. Total RNA concentration and purity were analyzed in duplicate using a NanoDrop One (Thermo Fisher Scientific, Inc.; cat. no. AZY1705838). cDNA was synthesized from qualified 1,000 ng RNA using an RT-PCR reverse transcription kit (Hifair® III 1st Strand cDNA Synthesis SuperMix for qPCR (gDNA digester plus), Shanghai Yeasen Biotechnology Co., Ltd.). The reverse transcription temperature protocol was: 25°C for 5 min, 55°C for 15 min, and 85°C for 5 min, as per the manufacturer's protocol. cDNA was stored at -20°C until required or kept on ice if used immediately. qPCR was performed using SYBR Green PCR reagents (Hieff UNICON® qPCR SYBR Green Master Mix; Shanghai Yeasen Biotechnology Co., Ltd.) on a ROCHE LightCycler 480 II detection system. The thermocycling conditions were: 95°C for 10 min; followed by 40 cycles at 95°C for 10 sec and 60°C for 30 sec. *GAPDH* was used as the internal control, and relative mRNA levels were calculated using the 2^{-ΔΔCq} method (59). Primers (sequences provided in Table I) were designed using Primer Bank (<https://pga.mgh.harvard>).

Table I. Sequences of the primers used.

Gene symbol	Forward primer (5'-3')	Reverse primer (5'-3')
CCNA1	GAGGTCCCGATGCTTGTGTCAG	GTTAGCAGCCCTAGCACTGTC
CCNA2	CGCTGGCGGTACTGAAGTC	GAGGAACGGTGACATGCTCAT
CCNB1	AATAAGGCGAAGATCAACATGGC	TTTGTACCAATGTCCCAAGAG
CCNB2	CCGACGGTGTCCAGTGATTT	TGTTGTTTTGGTGGGTTGAACT
CCNB3	ATGAAGGCAGTATGCAAGAAGG	CATCCACACGAGGTGAGTTGT
CCNC	CCTTGCATGGAGGATAGTGAATG	AAGGAGGATACAGTAGGCAAAGA
CCND1	GCTGCGAAGTGGAAACCATC	CCTCCTTCTGCACACATTTGAA
CCND2	ACCTTCCGCAGTGCTCCTA	CCCAGCCAAGAAACGGTCC
CCND3	TACCCGCCATCCATGATCG	AGGCAGTCCACTTCAGTGC
CCNE1	GCCAGCCTTGGGACAATAATG	CTTGCACGTTGAGTTTGGGT
CCNE2	TCAAGACGAAGTAGCCGTTTAC	TGACATCCTGGGTAGTTTTCTCCT
CCNF	CCCCGAAGATGTGCTCTTTCA	GCCTTCATTGTAGAGGTAGGCT
CCNG1	GAGTCTGCACACGATAATGGC	GTGCTTGGGCTGTACCTTCA
CCNG2	TCTCGGGTTGTTGAACGTCTA	GTAGCCTCAATCAAACCTCAGCC
CCNH	TGTTCGGTGTTAAGCCAGCA	TCCTGGGGTGATATTCCATTACT
GAPDH	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG




Figure 1. Transcriptional expression of the cyclin genes in different types of cancer compared with the respective normal tissue. CNS, central nervous system.

edu/primerbank/) and were synthesized by Guangzhou IGE Biotechnology, Ltd. Primer targets were confirmed using NCBI blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast/primer-tool.cgi?ctg_time=1656555059&job_key=6OI3EQEuDIYruAm9BN0tj37GPL1T1SegUg).

Bioinformatics analysis. Oncomine (60), an online large-scale tumor gene chip database, can be used to analyze the transcriptional expression levels of cyclin genes in clinical breast cancer samples compared with normal breast tissues (Fold change=2, P<0.001, top 10% gene rank, for screening out samples with relatively significant differential expression in cyclin genes).

GEPIA (61) is primarily used for differential expression analysis between cancer and normal tissues, and for

correlation analysis between gene expression and clinical pathological stage. The OS and risk-score analyses of breast cancer patients were assessed using Kaplan-Meier Plotter (62) and METABRIC using the auto-select best cutoff. cBioportal (63) was further used to analyze the genomic profiles of cyclin genes in TCGA, and analyze the relationship amongst genes through protein-protein interaction (PPI) analysis.

Database for annotation, visualization, and integrated discovery (DAVID) knowledgebase. DAVID contains species-specific gene/protein identifiers and their annotations from a variety of public genomic resources such as NCBI, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG), amongst others, to allow the incorporation




Figure 2. mRNA expression levels of the cyclin genes in healthy, tumor-adjacent, and tumor tissues.




Figure 3. Relationship between mRNA expression levels of the cyclin genes and the clinicopathological stages in breast cancer patients. TPM, transcripts per million.

of a diverse range of arrays of functional and sequencing annotations, greatly enriching the level of biological information available for a required gene (e.g. gene ID, pathways, etc.) (64). In this study, the GO and KEGG enrichment analysis of cyclin genes by DAVID were used to explore the functions and mechanisms of cyclin genes, R-4.0.4 (65,66) was used to draw figures.

Statistical analysis. A one-way ANOVA was used to compare the differences between multiple groups; a post-hoc Dunnett's multiple comparisons test was used to compare the mean of each column with the mean of the control group (MCF-10A). All statistical analyses were performed in GraphPad Prism version 9 (GraphPad Software, Inc.). For all bioinformatics analysis, all analyses were performed by the specific tools used in the corresponding website. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Transcriptional expression of the cyclin genes in breast cancer patients. The transcriptional expression levels of the cyclin genes in breast cancer and normal breast tissues were compared using data obtained from Oncomine (Fig. 1). *CCNA2*, *CCNB1*, *CCNB2*, *CCND1*, *CCND3*, *CCNE1*, *CCNE2*, and *CCNF* expression was upregulated in the tumor tissues; *CCND3* and *CCNE1* expression was moderately upregulated, whereas the rest of the genes exhibited significant upregulation. Of note, *CCNA2* mRNA expression in one of the datasets was significantly lower in the breast cancer tissues. Similarly, *CCND1* mRNA expression was slightly downregulated in one of the datasets. The mRNA expression levels of *CCNA1*, *CCND2*, *CCNG1*, and *CCNH* were downregulated in the tumor tissues, particularly *CCND2*. Of note, the transcriptional expression of *CCNB3*, *CCNC*, and *CCNG2* had not been collected in the Oncomine database.




Figure 4. Association between cyclin genes and survival rate. (A) Correlation analysis between the transcriptional levels of the cyclin genes and the survival of patients with breast cancer. (B) Risk-score analysis of cyclin gene expression. HR, hazard ratio.

Relationship between the mRNA expression of cyclin genes and clinicopathological stages of breast cancer. Comparative analysis of the transcriptional expression of cyclin genes in breast cancer tissues, tumor-adjacent tissues, and normal breast tissues in the GEPIA database demonstrated that the

mRNA expression of *CCNA2*, *CCNB1*, *CCNB2*, *CCNB3*, *CCNC*, *CCND1*, *CCNE1*, *CCNE2*, and *CCNF* in breast cancer and tumor-adjacent tissues was higher than that in the normal breast tissues (Fig. 2), whereas *CCNA1*, *CCND2*, *CCND3*, *CCNG1*, and *CCNH* mRNA expression was higher




Figure 5. Alteration analysis of cyclin gene expression in breast cancer.

in the normal tissues compared with the other tissues. *CCNG2* transcriptional expression did not differ significantly between tumors and normal tissues, and in both, its expression was lower compared with the tumor-adjacent tissues. We also analyzed the transcriptional expression of cyclin genes in the different clinical stages of breast cancer (Fig. 3). *CCNA2*, *CCNB1*, *CCNB2*, *CCNE1*, *CCNF* and *CCNG1* expression differed significantly, and the gene expression was highest in stage IV; however, the other genes did not exhibit differential expression based on stage.

Correlation between the transcriptional expression of the cyclin genes and the survival period of patients with breast cancer. To further explore the role of cyclin genes in the survival of breast cancer patients, Kaplan-Meier Plotter was used (Fig. 4A). The results showed that lower expression of *CCNA2*, *CCNB1*, *CCNB2*, *CCNE1*, *CCNE2*, and *CCNF* and higher expression of *CCND2*, *CCND3*, *CCNG1*, *CCNG2*, and *CCNH* was significantly correlated with a better OS ($P < 0.05$). However, high expression of *CCNB3* mRNA was not associated with OS in patients ($P = 0.13$). The curve trend showed that OS was longer if the transcriptional expression of *CCNC* was further reduced ($P = 0.064$). The risk-score analysis provided basic evidence for the above survival analysis (Fig. 4B), the only thing lacking was the analysis of *CCNF*, but from the results, the relationship between low *CCNF* mRNA expression and high survival was unexpected.

Alterations of expression of the cyclin genes in breast cancer and correlation analysis. The online cBioportal tools were used to analyze the alterations of cyclin genes and the related correlation in invasive breast cancer from TCGA. Among the samples from 1,084 breast cancer patients, various alterations were detected in 679 samples (Fig. 5). Mutations including inframe, missense, splicing, and truncations occurred in 18 samples, fusion-mutations occurred only in 1 sample, amplification occurred in 161 samples, deep deletions occurred in 12 samples, upregulated mRNA expression was observed in 105 samples, downregulated mRNA expression was observed in 121 samples, upregulated protein expression was observed in 15

samples, downregulated protein expression was observed in 18 samples, and multiple alterations were observed in 228 samples.

As shown in the specific variation analysis, the mRNA expression of *CCNA1*, *CCNC*, *CCND3*, *CCNE1*, and *CCNB3* was upregulated, and that of *CCNA2*, *CCNB1*, *CCNB2*, *CCND2*, *CCNG1*, *CCNG2*, and *CCNH* was downregulated. Gene amplifications were more pronounced with *CCND1*, *CCNE2*, and *CCNF*. Furthermore, a fusion mutation was observed in the *CCNF* gene.

Based on the correlation analysis among the cyclin genes (Fig. 6), for cyclin genes and other interacting genes, the majority of shared protein domains accounted for 69.48% of the total interacting network nodes, predicted and co-expression accounted for 14.21 and 9.12%, respectively, and the remaining accounted for <10%.

Cyclin gene functions and molecular signaling pathways based on GO and KEGG enrichment analysis. Functional involvement of cyclin genes such as biological processes (BP) was predicted using GO enrichment analysis. The results showed that cell division (GO: 0051301), regulation of cell cycle (GO: 0051726), positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO: 0045737), G1/S transition of mitotic cell cycle (GO: 0000082), and regulation of cyclin-dependent protein serine/threonine kinase activity (GO: 0000079) were significantly affected by cyclin genes in BP (Fig. 7A).

KEGG enrichment analysis indicated that there were 18 molecular signaling pathways that cyclin genes participated in (Fig. 7B). Signaling pathways closely associated with breast cancer included the Wnt signaling pathway (map04310), PI3K-Akt signaling pathway (map04151), p53 signaling pathway (map04115), microRNAs in cancer (map05206), JAK-STAT signaling pathway (map04630), hippo signaling pathway (map04390), cell cycle (map04110), and AMPK signaling pathway (map04152); the cyclin genes were mostly involved in cell cycle regulation and p53 signaling pathway.

Expression of the cyclin genes in the breast cancer cell lines. To verify cyclin gene expression *in vitro*, RT-qPCR analysis of the breast cancer cell lines was performed using MCF-10A cells as




Figure 6. PPI network based on the cyclin genes.

the standard control. The results demonstrated that the mRNA expression levels of most of the cyclin genes in SK-BR-3 were lower than that in control, except for *CCND1* and *CCNE1* mRNA expression, whose expression was slightly higher (Fig. 8). The mRNA expression levels of *CCNA2*, *CCNB1*, *CCNB2*, *CCNB3*, *CCND1*, *CCNE1*, *CCNE2*, and *CCNF* in the cancer cell lines were significantly higher than that in MCF-10A cells, whereas *CCND3* and *CCNG2* exhibited lower expression. *CCNA1* and *CCNG2* mRNA expression varied based on the breast cancer cell line, and *CCND2* was barely expressed in any of the cell lines. In summary, these results are generally consistent with the gene expression analysis of the data from the databases. However, the mRNA expression levels of *CCNC* and *CCNH* in cell lines were lower and higher than that in MCF-10A cells, respectively; their expression in tissues showed the opposite trend compared with that in the cell lines.

Discussion

The cyclin genes play significant roles in a variety of malignant tumors (4-11), and evaluation of the transcriptional

expression levels of the different cyclin genes may be used to predict the prognosis and assess drug efficacy in malignant tumors. However, studies assessing this are lacking due to the numerous sub-types of cyclin genes and the high degree of heterogeneity in breast cancer. Thus, the present study aimed to analyze and discuss the value of the analysis of the diverse range of cyclin genes in breast cancer at the transcriptional level, using online public databases and bioinformatics methods to identify potential biomarkers to improve survival and prognostic prediction, and/or serve as therapeutic targets.

The functions of different cyclin genes vary in enrichment analysis, and regulation, in general, is associated with the phase of the cell cycle (67-72). However, in the enrichment analysis of breast cancer-related molecular signaling pathways, the regulation of *CCNC* and *CCNF* was not involved. Therefore, certain cyclin genes, especially *CCNC* and *CCNF*, may have greater value as potential biomarkers based on our results.

First, the median transcriptional expression of *CCNA1* in breast cancer tissue was lower than that in tumor-adjacent and normal breast tissues. The protein encoded by *CCNA1* is




Figure 7. Relative molecular pathway analysis. (A) GO-BP and (B) KEGG enrichment analysis.

involved in the process of anthracycline resistance, and the methylation status of *CCNA1* and *CCND2* in normal tissues was lower in normal breast tissues than that in tumors, and its expression in breast cancer was downregulated after treatment (5,73,74). These data indicated that high transcriptional expression of *CCNA1* and *CCND2* may slow down the process of acquisition of resistance to anthracyclines and prolong the effects of the drug in breast cancer cells. Therefore, they may be used to predict anthracycline/filomycin sensitivity. Secondly, there were no significant differences in the mRNA expression levels of *CCNA1* between the clinical tumor stages of breast cancer. The results showed that its high expression could significantly increase the patients' RFS, while low expression increased the patients' OS, although the difference was not significant. From the analysis of TCGA data, *CCNA1* mRNA was mainly highly expressed in breast cancer caused by mutations. The contradictory results may be due to the fact that mutations may frequently occur due to alterations in breast cancer heterogeneity during disease development or treatment (15). Previous studies on the investigation of *CCNA1* expression in breast cancer are lacking; however, based on these results, *CCNA1* may exhibit potential as a biomarker for evaluating drug tolerance in breast cancer.

CCNA2 is a relatively more reliable biomarker for predicting the prognosis and assessing drug resistance. Gao *et al* (18) confirmed that *CCNA2* was powerful in predicting the survival prognosis of ER-positive breast cancer patients. Overexpression of *CCNA2* mRNA could lead to Tamoxifen resistance. However, additional evidence is required to understand the mechanism by which tamoxifen resistance is reversed. In this study, the mRNA expression levels of *CCNA2*

in breast cancer were significantly higher than that in normal tissues, highlighting the potential of *CCNA2* as a biomarker. Additionally, its expression in different clinical stages of breast cancer varied significantly. Based on survival length, lower transcriptional expression of *CCNA2* was significantly correlated with a better OS and RFS in cancer patients, a result consistent with a previous study (75). Additionally, the mRNA expression levels of *CCNA2* in one dataset were significantly lower than that in normal tissues, and analysis of data from TCGA also showed that *CCNA2* mRNA was lower in normal tissues. Furthermore, *CCNA2* mRNA expression was lower in SK-BR-3 cells than in MCF-10A cells. Together, the results not only reflect the heterogeneity of breast cancer (15), but also provide a novel direction for the in-depth investigation of breast cancer. Thus, future studies should analyze *CCNA2* expression for predicting prognosis and evaluating its clinical efficacy.

Similar to *CCNA2*, *CCNB1*, and *CCNB2* show significant potential for predicting the prognosis and assessing drug resistance. In both tumor tissues and cancer cell lines, the mRNA expression levels of *CCNB1* and *CCNB2* were significantly higher than that in normal tissues and cells. The low transcriptional expression of the two genes may indicate a better OS in patients, consistent with previous studies (22,75-77). It has also been found that their high transcriptional expression can result in tamoxifen resistance and is positively correlated with endocrine resistance (22,78).

Unlike *CCNB1* and *CCNB2*, *CCNB3* in breast cancer has not been extensively studied and thus could not be validated. Corresponding mRNA expression data was not available in the Oncomine database. Transcriptional expression of *CCNB3*




Figure 8. Relative mRNA expression levels of the cyclin genes in different breast cancer cell lines * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$.

in breast cancer was slightly higher than that in the normal tissues, and the *in vitro* analysis showed the same trend. In TCGA analysis, the number of samples that showed upregulated or downregulated expression of *CCNB3* mRNA was approximately the same. Although the P -value was > 0.05 , the survival curve showed a trend such that the upregulated expression of *CCNB3* mRNA may predict an improved OS for patients. At present, whether *CCNB3* is suitable for future use to judge the prognosis in patients with breast cancer and the efficacy of drug response is still open for discussion, a definite correlation between *CCNB3* and breast cancer has been confirmed. Additional studies are required to explore the biological function of *CCNB3*.

Analysis of the GEPIA dataset showed that *CCNC* mRNA expression in breast cancer was significantly higher than that in normal tissues, similar to the primary alteration in TCGA data. There were also a small number of mutations with lower transcriptional expression. In the breast cancer cell lines, *CCNC* mRNA expression was lower than that in MCF-10A cells. Li *et al* (79) showed that *CCNC* regulates the expression of the *NOTCH1* oncogene to exert a tumor suppressor effect. Thus far, a more direct explanation for the low expression of *CCNC* mRNA is lacking. Tumor cells may adopt various means to circumvent the inhibitory effects of *CCNC* to grow. Additionally, *CCNC* is also involved in the transcriptional

regulation of *SRC2* in human breast cancer, and their expression was positively correlated (80). *SRC* is upregulated in the early stages of breast intraductal carcinoma compared with normal breast tissue. Decreased expression of *SRC2* was associated with the progression of the disease and the formation of invasive ductal carcinoma (81), thus it is highly likely that *CCNC* mRNA expression may be similarly altered with *SRC2*. It has been suggested that *CCNC* participates in the RB-E2F pathway during the progression of breast cancer (31), and its expression may also vary as the disease progresses. Therefore, it may serve as a potential therapeutic target for repressing the cell cycle and a novel prognostic predictor.

CCND1, an oncogene, is currently the most extensively studied gene related to endocrine resistance (39,82). Its expression was significantly increased in hormone receptor-positive breast cancer (38) and was closely related to mechanisms of endocrine resistance. *CCND1* has been used in HER-2-positive breast cancer as a continuous variable marker to predict the therapeutic benefit of trastuzumab (83). In addition, *CCND1* had a different relationship with the aggressiveness of tumors and its low transcriptional expression may enhance the migration of breast cancer subgroups (43,84). In this study, *CCND1* mRNA expression in breast cancer was significantly increased. Its low expression was shown to correlate with a better RFS in patients with breast cancer, consistent with previous

studies (36,37). Analysis of the Oncomine dataset showed that the expression of *CCND1* mRNA in breast cancer was lower than that in normal tissues, and the same trend of expression in breast cancer samples was found in TCGA, providing evidence for why the low expression of *CCND1* can enhance the migration of breast cancer sub-types. Based on the above findings, it is understandable that *CCND1* may serve as a biomarker for breast cancer diagnosis, prognostic prediction, drug efficacy, and resistance.

CCND2 mRNA expression was significantly lower in breast cancer samples compared with the normal tissues in several databases including Oncomine, GEPIA, and TCGA. Its high expression was typically associated with a better OS and RFS, consistent with previous reports (42,85). Further studies showed that *CCND2* methylation was negatively correlated with its gene expression (43,86). The integrated analysis of the correlation between *CCND2* methylation and gene expression may be used to improve the predictive performance of breast cancer outcomes, which may be conducive to the expansion of the potential clinical applications of *CCND2*.

The Oncomine dataset showed that *CCND3* expression was highly upregulated in breast cancer and its mRNA expression was upregulated in the TCGA dataset. Analysis of the GEPIA dataset illustrated that *CCND3* mRNA expression was high in normal breast tissues, and the RT-qPCR results showed that *CCND3* mRNA expression in MCF-10A cells was higher than that in other cancer cell lines. Based on the survival analysis it was shown that upregulated expression of *CCND3* mRNA was associated with a better OS. Conversely, Justenhoven *et al* (87) found that the low expression of *E2F2*, *CCND1*, and *CCND3* genes reduced the levels of factors that downregulate HER-2, thereby allowing upregulated expression of HER-2 in tumors, and it is hypothesized that these three gene sub-types are potential indicators of HER-2 status in breast cancer. Combining all the results of the databases together, it can be suggested that *CCND3* plays various functions in different breast cancer sub-types. Since the current exploration of *CCND3* is still limited, further research is required to better understand the potential of *CCND3* as a possible biomarker for prognostic prediction and improving drug efficacy.

The expression of *CCNE1* and *CCNE2*, two subtypes of the *CCNE* gene, was approximately the same. The expression of both of these genes was upregulated in breast cancer, a result that was confirmed by RT-qPCR. Patients with low transcriptional levels of both genes in breast cancer had a significantly better OS. One difference between the two subtypes was that the expression of *CCNE1* was correlated with the clinical tumor stage. The clinical trials PALPMA-3 and POP (88) demonstrated that the efficacy of Palbociclib decreased when *CCNE1* mRNA expression was increased. Therefore, *CCNE1* mRNA is predictive of metastatic tumors. Previously it has been shown that the amplification of *CCNE1* was associated with a poorer OS of metastatic triple-negative breast cancer, and it was speculated that this phenomenon may be caused by *CCNE1* upregulation-induced chemotherapeutic resistance (89). Moreover, both *CCNE1* and *CCNE2* could be used as independent prognostic markers for patients with lymph node-negative breast cancer (90). Thus, as typical oncogenes, *CCNE1* and *CCNE2* may be employed as factors for the prognostic prediction and for countering drug resistance mechanisms in breast cancer.

The functional involvement of *CCNF* in breast cancer remains unclear. Studies have used *CCNF* as a target gene for RNAi targeting in breast cancer (91,92). *CCNF* may be involved in the non-KEGG-enriched molecular signaling pathways to regulate drug resistance in breast cancer. Additionally, the *CCNF* protein possesses a unique characteristic, an F-BOX homologous sequence, which is suggestive of *CCNF* possessing a similar function to that of F-BOX. As for F-BOX, high mRNA expression of its subtypes (*FBXO1*, *FBXO31*, and *FBXO5*) may serve as biomarkers for predicting prognosis, and their expression was significantly correlated with a poor prognosis in patients with breast cancer (93). Therefore, it was hypothesized that *CCNF* may be used as a biomarker similar to F-BOX. In this study, *CCNF* mRNA expression was upregulated in breast cancer, and it was primarily observed as gene amplification and the only example of a fusion alteration found in TCGA in the present study. The clinical stage of breast cancer was significantly related to the differential expression of *CCNF*, and patients with low *CCNF* mRNA expression had a significantly better OS. Therefore, *CCNF* has potential as an advanced biomarker for prognostic prediction and as a gene target for counteracting therapeutic tolerance.

CCNG1 is the only cyclin gene that has both positive and negative effects on cellular growth (94,95) as the cyclinG1 protein encoded by *CCNG1* is highly unstable. Tian *et al* (96) found out that the administration of estrogen and progesterone promoted cell proliferation and upregulated the expression of cyclinG1 in MCF-7 cells. Estradiol and progesterone-mediated cell viability and clonal ability were restricted after *CCNG1* was knocked down using shRNA, suggesting that estradiol and progesterone promote cell proliferation in breast cancer partially by inducing cyclinG1 expression. In the present study, *CCNG1* mRNA expression was low in breast cancer, and cancer patients with upregulated *CCNG1* expression had a better OS. *CCNG1* expression was also significantly associated with the clinicopathological stage. Taken together, despite the instability of the protein encoded by *CCNG1*, it may still serve as a biomarker for evaluating the prognosis of breast cancer and as a therapeutic target in certain subtypes of breast cancer.

As an estrogen-regulated gene, *CCNG2* has previously been used as a target gene for judging the efficacy of endocrine-based medicine, as low *CCNG2* mRNA expression is indicative of a poorer prognosis. In the present study, *CCNG2* mRNA expression in breast cancer tissues was higher than that in normal tissues although the difference was not statistically significant. RT-qPCR analysis showed that *CCNG2* mRNA expression was higher in MCF-7 cells and lower in MDA-MB-231 and BT-549 cells, and patients with high transcriptional expression of *CCNG2* had a better OS. Consistent with a previous study (57), *CCNG2* expression was downregulated in highly aggressive breast cancer subtypes with poor prognoses. Consequently, *CCNG2* may exhibit potential for the prognostic prediction of ER-positive breast cancer and as a therapeutic target. However, additional studies on *CCNG2* in other subtypes of breast cancer are required to examine its value as a biomarker.

Studies on the expression or the function of *CCNH* in breast cancer are limited. Shahi *et al* (97) performed whole-exome sequencing of 492 cancer-related genes as well as high-risk genes and mutation analysis of *BRCA1* and *BRCA2* negative

breast cancer patients. In total, 31 gene variants/genes were identified for breast cancer susceptibility predisposition including *CCNH*. However, *CCNH* has not been extensively studied with regard to familial breast cancer. In the present study, *CCNH* expression was low in breast cancer, and upregulated expression was predictive of a better OS. It has been indirectly shown that the increased expression of *CCNH* in ER-positive breast cancer was associated with indicators of good prognosis (98). Yet, RT-qPCR analysis of breast cancer cell lines showed higher *CCNH* mRNA expression than that in MCF-10A. At present, there is currently no sufficient evidence to explain this phenomenon. Thus, further studies are required to determine the value of *CCNH* as a biomarker for evaluating the prognosis and exploring the mechanisms of drug action.

In conclusion, we systematically analyzed the expression of the cyclin genes in breast cancer based on its value in predicting prognosis and evaluating drug efficacy, enabling a deeper understanding of the heterogeneity of breast cancer. Our results indicated that *CCNA2*, *CCNBI*, *CCNB2*, *CCND1*, *CCND2*, *CCNE1*, and *CCNE2* may be mature and valid biomarkers in predicting prognosis and judging efficacy. *CCNG1* and *CCNG2* may be used as biological markers in specific types of breast cancer. At present, there are few relevant studies on *CCNA1*, *CCNB3*, *CCNC*, *CCND3*, *CCNF*, and *CCNH* in breast cancer; however, the results of the present and previous studies showed their potential as unique predictors of prognosis and potential targets for countering therapeutic resistance. Together, the discovery of novel biomarkers and gene targets will facilitate the exploration of more personalized therapeutic strategies; however, further studies are required to verify their biological functions.

Acknowledgements

Not applicable.

Funding

This study was supported by funding from the National Nature Science Foundation of China, The Third Affiliated Hospital of Kunming Medical University: Yunnan Cancer Center, Kunming, Yunnan, China (grant nos. 81760480 and 81960479).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

NQL, WHC and JN confirm the authenticity of all the raw data. NQL participated in the design of study, and was responsible for collecting and interpreting data, performing the bioinformatics analysis, visualizing the presentation, and drafting and revising the original manuscript. WHC collected the data, performed the bioinformatics analysis and drafted the original manuscript. XW and JC participated in data curation, confirmed and analyzed the data, and assisted in drafting the revised manuscript. JN mainly provided the research conceptualization and funding support, supervised

and assisted in designing the study, and participated in the revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Cai Z and Liu Q: Cell cycle regulation in treatment of breast cancer. *Adv Exp Med Biol* 1026: 251-270, 2017.
2. Steeg PS and Zhou Q: Cyclins and breast cancer. *Breast Cancer Res Treat* 52: 17-28, 1998.
3. Bai C, Richman R and Elledge SJ: Human cyclin F. *EMBO J* 13: 6087-6098, 1994.
4. Ye C, Wang J, Wu P, Li X and Chai Y: Prognostic role of cyclin B1 in solid tumors: A meta-analysis. *Oncotarget* 8: 2224-2232, 2017.
5. Lee YS, Ryu SW, Bae SJ, Park TH, Kwon K, Noh YH and Kim SY: Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer. *Oncol Rep* 33: 1985-1993, 2015.
6. Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, *et al*: Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. *Cancer Res* 76: 2453-2464, 2016.
7. Li R, Jiang X, Zhang Y, Wang S, Chen X, Yu X, Ma J and Huang X: Cyclin B2 overexpression in human hepatocellular carcinoma is associated with poor prognosis. *Arch Med Res* 50: 10-17, 2019.
8. Dorn J, Spatz H, Schmieder M, Barth TF, Blatz A, Henne-Bruns D, Knippschild U and Kramer K: Cyclin H expression is increased in GIST with very-high risk of malignancy. *BMC Cancer* 10: 350, 2010.
9. Huang KC, Yang J, Ng MC, Ng SK, Welch WR, Muto MG, Berkowitz RS and Ng SW: Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. *Eur J Cancer* 67: 152-163, 2016.
10. Chujan S, Kitkumthorn N, Siriengkul S and Mutirangura A: *CCNA1* promoter methylation: A potential marker for grading Papanicolaou smear cervical squamous intraepithelial lesions. *Asian Pac J Cancer Prev* 15: 7971-7975, 2014.
11. Takashima S, Saito H, Takahashi N, Imai K, Kudo S, Atari M, Saito Y, Motoyama S and Minamiya Y: Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer. *Tumour Biol* 35: 4257-4265, 2014.
12. Wiseman M: The second world cancer research fund/American institute for cancer research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. *Proc Nutr Soc* 67: 253-256, 2008.
13. Harbeck N and Gnant M: Breast cancer. *Lancet* 389: 1134-1150, 2017.
14. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71: 209-249, 2021.
15. Zeng X, Liu C, Yao J, Wan H, Wan G, Li Y and Chen N: Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications. *Pharmacol Res* 163: 105320, 2021.
16. Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, *et al*: Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. *Blood* 119: 5492-5501, 2012.

17. Yang R, Nakamaki T, Lübbert M, Said J, Sakashita A, Freyaldenhoven BS, Spira S, Huynh V, Müller C and Koeffler HP: Cyclin A1 expression in leukemia and normal hematopoietic cells. *Blood* 93: 2067-2074, 1999.
18. Gao T, Han Y, Yu L, Ao S, Li Z and Ji J: CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. *PLoS One* 9: e91771, 2014.
19. Hein JB and Nilsson J: Interphase APC/C-Cdc20 inhibition by cyclin A2-Cdk2 ensures efficient mitotic entry. *Nat Commun* 7: 10975, 2016.
20. Pei J, Zhang J, Yang X, Wu Z, Sun C, Wang Z and Wang B: NEK5 promotes breast cancer cell proliferation through up-regulation of cyclin A2. *Mol Carcinog* 58: 933-943, 2019.
21. Ding K, Li W, Zou Z, Zou X and Wang C: CCNB1 is a prognostic biomarker for ER+ breast cancer. *Med Hypotheses* 83: 359-564, 2014.
22. Liu HY, Liu YY, Yang F, Zhang L, Zhang FL, Hu X, Shao ZM and Li DQ: Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. *Nucleic Acids Res* 48: 3638-3656, 2020.
23. Yu AQ, Wang ZX, Wu W, Chen KY, Yan SR and Mao ZB: Circular RNA CircCCNB1 sponges micro RNA-449a to inhibit cellular senescence by targeting CCNE2. *Aging (Albany NY)* 11: 10220-10241, 2019.
24. Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K: Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. *BMC Cancer* 13: 1, 2013.
25. Qian X, Song X, He Y, Yang Z, Sun T, Wang J, Zhu G, Xing W and You C: CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients. *Biomed Pharmacother* 74: 222-227, 2015.
26. Gao Z, Man X, Li Z, Bi J, Liu X, Li Z, Zhu Y, Zhang Z and Kong C: Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. *Oncol Rep* 41: 2440-2452, 2019.
27. Lozano JC, Perret E, Schatt P, Arnould C, Peaucellier G and Picard A: Molecular cloning, gene localization, and structure of human cyclin B3. *Biochem Biophys Res Commun* 291: 406-413, 2002.
28. Han H, Bertrand KC, Patel KR, Fisher KE, Roy A, Muscal JA and Venkatramani R: BCOR-CCNB3 fusion-positive clear cell sarcoma of the kidney. *Pediatr Blood Cancer* 67: e28151, 2020.
29. Yoshida A, Arai Y, Hama N, Chikuta H, Bando Y, Nakano S, Kobayashi E, Shibahara J, Fukuhara H, Komiyama M, *et al*: Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. *Histopathology* 76: 509-520, 2020.
30. Shibayama T, Okamoto T, Nakashima Y, Kato T, Sakurai T, Minamiguchi S, Kataoka TR, Shibuya S, Yoshizawa A, Toguchida J and Haga H: Screening of BCOR-CCNB3 sarcoma using immunohistochemistry for CCNB3: A clinicopathological report of three pediatric cases. *Pathol Int* 65: 410-414, 2015.
31. Ren S and Rollins BJ: Cyclin C/cdk3 promotes Rb-dependent G0 exit. *Cell* 117: 239-251, 2004.
32. Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M and Nimer SD: Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. *Stem Cells* 28: 308-317, 2010.
33. Xu W and Ji JY: Dysregulation of CDK8 and cyclin C in tumorigenesis. *J Genet Genomics* 38: 439-452, 2011.
34. Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M and Bay BH: Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. *Int J Oncol* 37: 483-492, 2010.
35. Roy PG and Thompson AM: Cyclin D1 and breast cancer. *Breast* 15: 718-127, 2006.
36. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS and Ellis IO: CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. *Breast Cancer Res Treat* 109: 325-335, 2008.
37. He Q, Wu J, Liu XL, Ma YH, Wu XT, Wang WY and An HX: Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: A meta-analysis. *J BUON* 22: 1209-1216, 2017.
38. Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, *et al*: Expression of cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. *Breast Cancer Res Treat* 168: 179-187, 2018.
39. Shi Q, Li Y, Li S, Jin L, Lai H, Wu Y, Cai Z, Zhu M, Li Q, Li Y, *et al*: LncRNA DILA1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. *Nat Commun* 11: 5513, 2020.
40. Pors J, Naso J, Berg K and Churg A: Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations. *Mod Pathol* 33: 312-318, 2020.
41. Kwapisz D: Cyclin-dependent kinase 4/6 inhibitors in breast cancer: Palbociclib, ribociclib, and abemaciclib. *Breast Cancer Res Treat* 166: 41-54, 2017.
42. Hung CS, Wang SC, Yen YT, Lee TH, Wen WC and Lin RK: Hypermethylation of CCND2 in lung and breast cancer is a potential biomarker and drug target. *Int J Mol Sci* 19: 3096, 2018.
43. Callahan CL, Wang Y, Marian C, Weng DY, Eng KH, Tao MH, Ambrosone CB, Nie J, Trevisan M, Smiraglia D, *et al*: DNA methylation and breast tumor clinicopathological features: The western New York exposures and breast cancer (WEB) study. *Epigenetics* 11: 643-652, 2016.
44. Ding ZY, Li R, Zhang QJ, Wang Y, Jiang Y, Meng QY, Xi QL and Wu GH: Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis. *Cancer Med* 8: 2717-2729, 2019.
45. Luhtala S, Staff S, Tanner M and Isola J: Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. *Tumour Biol* 37: 9813-9823, 2016.
46. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, *et al*: Cyclin E and survival in patients with breast cancer. *N Engl J Med* 347: 1566-1575, 2002.
47. Lee C, Fernandez KJ, Alexandrou S, Sergio CM, Deng N, Rogers S, Burgess A and Caldon CE: Cyclin E2 promotes whole genome doubling in breast cancer. *Cancers (Basel)* 12: 2268, 2020.
48. Peek GW and Tollefsbol TO: Combinatorial PX-866 and raloxifene decrease Rb phosphorylation, cyclin E2 transcription, and proliferation of MCF-7 breast cancer cells. *J Cell Biochem* 117: 1688-1696, 2016.
49. Lindskog C: The potential clinical impact of the tissue-based map of the human proteome. *Expert Rev Proteomics* 12: 213-215, 2015.
50. Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun J and Zhang CZ: Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. *Cancer Sci* 104: 508-515, 2013.
51. Zhao L, Jiang L, He L, Wei Q, Bi J, Wang Y, Yu L, He M, Zhao L and Wei M: Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. *J Cell Physiol* 234: 6350-6360, 2019.
52. Noh JM, Kim J, Cho DY, Choi DH, Park W and Huh SJ: Exome sequencing in a breast cancer family without BRCA mutation. *Radiat Oncol J* 33: 149-154, 2015.
53. Tamura K, Kanaoka Y, Jinno S, Nagata A, Ogiso Y, Shimizu K, Hayakawa T, Nojima H and Okayama H: Cyclin G: A new mammalian cyclin with homology to fission yeast Cig1. *Oncogene* 8: 2113-2118, 1993.
54. Zimmermann M, Arachchige-Don AP, Donaldson MS, Patriarchi T and Horne MC: Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival. *Cell Cycle* 15: 3278-3295, 2016.
55. Wu D, Han B, Guo L and Fan Z: Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis. *J Obstet Gynaecol* 36: 615-621, 2016.
56. Knowles LM and Smith JW: Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. *BMC Genomics* 8: 168, 2007.
57. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. *Proc Natl Acad Sci USA* 102: 13550-13555, 2005.
58. Mao L, Ling X and Chen J: Cyclin H regulates lung cancer progression as a carcinoma inducer. *Comput Math Methods Med* 2021: 6646077, 2021.
59. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
60. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. *Neoplasia* 6: 1-6, 2004.

61. Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 45 (W1): W98-W102, 2017.
62. Nagy Á, Munkácsy G and Gyórfy B: Pancancer survival analysis of cancer hallmark genes. *Sci Rep* 11: 6047, 2021.
63. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, *et al*: Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. *Cell* 173: 291-304.e6, 2018.
64. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4: 44-57, 2009.
65. R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2012.
66. RStudio Team: RStudio: Integrated Development for R. RStudio, Inc., Boston, MA, 2015.
67. Tang T, Guo C, Xia T, Zhang R, Zen K, Pan Y and Jin L: LncCCAT1 promotes breast cancer stem cell function through activating WNT/ β -catenin signaling. *Theranostics* 9: 7384-7402, 2019.
68. Shao F, Pang X and Baeg GH: Targeting the JAK/STAT signaling pathway for breast cancer. *Curr Med Chem* 28: 5137-5151, 2021.
69. Costa RLB, Han HS and Gradishar WJ: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. *Breast Cancer Res Treat* 169: 397-406, 2018.
70. Li X, Zeng Z, Wang J, Wu Y, Chen W, Zheng L, Xi T, Wang A and Lu Y: MicroRNA-9 and breast cancer. *Biomed Pharmacother* 122: 109687, 2020.
71. Qiao K, Ning S, Wan L, Wu H, Wang Q, Zhang X, Xu S and Pang D: LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway. *J Exp Clin Cancer Res* 38: 418, 2019.
72. Lee MG, Kwon YS, Nam KS, Kim SY, Hwang IH, Kim S and Jang H: Chaga mushroom extract induces autophagy via the AMPK-mTOR signaling pathway in breast cancer cells. *J Ethnopharmacol* 274: 114081, 2021.
73. Woo SH, Seo SK, An S, Choe TB, Hong SI, Lee YH and Park IC: Implications of caspase-dependent proteolytic cleavage of cyclin A1 in DNA damage-induced cell death. *Biochem Biophys Res Commun* 453: 438-442, 2014.
74. Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J and Kristensen VN: DNA methylation status of key cell-cycle regulators such as CDKN2A/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. *Clin Cancer Res* 20: 6357-6366, 2014.
75. Deng JL, Xu YH and Wang G: Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis. *Front Genet* 10: 695, 2019.
76. Tang J, Kong D, Cui Q, Wang K, Zhang D, Gong Y and Wu G: Prognostic genes of breast cancer identified by gene co-expression network analysis. *Front Oncol* 8: 374, 2018.
77. Jayanthi VSPKSA, Das AB and Saxena U: Grade-specific diagnostic and prognostic biomarkers in breast cancer. *Genomics* 112: 388-396, 2020.
78. Zhou H, Lv Q and Guo Z: Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years. *Mol Med Rep* 17: 3152-3157, 2018.
79. Li N, Fasl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, *et al*: Cyclin C is a haploinsufficient tumour suppressor. *Nat Cell Biol* 16: 1080-1091, 2014.
80. Bozickovic O, Hoang T, Fenne IS, Helland T, Skartveit L, Ouchida M, Mellgren G and Sagen JV: Cyclin C interacts with steroid receptor coactivator 2 and upregulates cell cycle genes in MCF-7 cells. *Biochim Biophys Acta* 1853: 2383-2391, 2015.
81. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S and Sonoo H: Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. *Clin Cancer Res* 6: 512-518, 2000.
82. Butt AJ, McNeil CM, Musgrove EA and Sutherland RL: Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E. *Endocr Relat Cancer* 12 (Suppl 1): S47-S59, 2005.
83. Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, *et al*: Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: A TransHERA study. *Clin Cancer Res* 24: 3079-3086, 2018.
84. Tobin NP, Sims AH, Lundgren KL, Lehn S and Landberg G: Cyclin D1, Id1 and EMT in breast cancer. *BMC Cancer* 11: 417, 2011.
85. Fischer H, Chen J, Skoog L and Lindblom A: Cyclin D2 expression in familial and sporadic breast cancer. *Oncol Rep* 9: 1157-1161, 2002.
86. Li Z, Heng J, Yan J, Guo X, Tang L, Chen M, Peng L, Wu Y, Wang S, Xiao Z, *et al*: Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients. *Breast Cancer Res Treat* 160: 371-383, 2016.
87. Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C, *et al*: Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. *Int J Cancer* 124: 2077-2081, 2009.
88. Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, *et al*: Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. *J Clin Oncol* 37: 1169-1178, 2019.
89. Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, *et al*: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. *BMC Cancer* 19: 96, 2019.
90. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, *et al*: Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. *Clin Cancer Res* 12: 3319-3328, 2006.
91. Seyhan AA, Varadarajan U, Choe S, Liu W and Ryan TE: A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. *Mol Biosyst* 8: 1553-1570, 2012.
92. Gupta ED, Pachauri M, Ghosh PC and Rajam MV: Targeting polyamine biosynthetic pathway through RNAi causes the abrogation of MCF 7 breast cancer cell line. *Tumour Biol* 37: 1159-1171, 2016.
93. Wang X, Zhang T, Zhang S and Shan J: Prognostic values of F-box members in breast cancer: An online database analysis and literature review. *Biosci Rep* 39: BSR20180949, 2019.
94. Piscopo DM and Hinds PW: A role for the cyclin box in the ubiquitin-mediated degradation of cyclin G1. *Cancer Res* 68: 5581-5590, 2008.
95. Liu F, Gao X, Yu H, Yuan D, Zhang J, He Y and Yue L: Effects of expression of exogenous cyclin G1 on proliferation of human endometrial carcinoma cells. *Chin J Physiol* 56: 83-89, 2013.
96. Tian JM, Ran B, Zhang CL, Yan DM and Li XH: Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression. *Braz J Med Biol Res* 51: 1-7, 2018.
97. Shahi RB, De Brakeleer S, Caljon B, Pauwels I, Bonduelle M, Joris S, Fontaine C, Vanhoeij M, Van Dooren S, Teugels E and De Grève J: Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. *BMC Cancer* 19: 313, 2019.
98. Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, *et al*: Expression of CDK7, cyclin H, and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor-positive breast cancer. *Clin Cancer Res* 22: 5929-5938, 2016.

